These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 25556617)

  • 41. Trabectedin in Ovarian Cancer: is it now a Standard of Care?
    Ventriglia J; Paciolla I; Cecere SC; Pisano C; Di Napoli M; Arenare L; Setola SV; Losito NS; Califano D; Orditura M; Pignata S
    Clin Oncol (R Coll Radiol); 2018 Aug; 30(8):498-503. PubMed ID: 29429842
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Real-World Outcomes of Combination Chemotherapy with Trabectedin plus Pegylated Liposomal Doxorubicin in Patients with Recurrent Ovarian Cancer: A Single-Center Experience.
    Moriceau G; Rivoirard R; Méry B; Vallard A; Pacaut C; Trone JC; Espenel S; Bosacki C; Jacquin JP; Magné N
    Chemotherapy; 2016; 61(3):122-6. PubMed ID: 26752402
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Trabectedin as single agent in relapsed advanced ovarian cancer: results from a retrospective pooled analysis of three phase II trials.
    del Campo JM; Sessa C; Krasner CN; Vermorken JB; Colombo N; Kaye S; Gore M; Zintl P; Gómez J; Parekh T; Park YC; McMeekin S
    Med Oncol; 2013 Mar; 30(1):435. PubMed ID: 23397080
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Trabectedin for the treatment of breast cancer.
    D'Incalci M; Zambelli A
    Expert Opin Investig Drugs; 2016; 25(1):105-15. PubMed ID: 26592307
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Prospective phase II trial of trabectedin in BRCA-mutated and/or BRCAness phenotype recurrent ovarian cancer patients: the MITO 15 trial.
    Lorusso D; Scambia G; Pignata S; Sorio R; Amadio G; Lepori S; Mosconi A; Pisano C; Mangili G; Maltese G; Sabbatini R; Artioli G; Gamucci T; Di Napoli M; Capoluongo E; Ludovini V; Raspagliesi F; Ferrandina G
    Ann Oncol; 2016 Mar; 27(3):487-93. PubMed ID: 26681678
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Trabectedin as a new chemotherapy option in the treatment of relapsed platinum sensitive ovarian cancer.
    Monk BJ; Dalton H; Benjamin I; Tanović A
    Curr Pharm Des; 2012; 18(25):3754-69. PubMed ID: 22591421
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Trabectedin: Ecteinascidin 743, Ecteinascidin-743, ET 743, ET-743, NSC 684766.
    Drugs R D; 2006; 7(5):317-28. PubMed ID: 16922593
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Cardiac safety of trabectedin monotherapy or in combination with pegylated liposomal doxorubicin in patients with sarcomas and ovarian cancer.
    Jones RL; Herzog TJ; Patel SR; von Mehren M; Schuetze SM; Van Tine BA; Coleman RL; Knoblauch R; Triantos S; Hu P; Shalaby W; McGowan T; Monk BJ; Demetri GD
    Cancer Med; 2021 Jun; 10(11):3565-3574. PubMed ID: 33960681
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Nibrin is a marker of clinical outcome in patients with advanced serous ovarian cancer treated in the phase III OVA-301 trial.
    Monk BJ; Kaye SB; Poveda A; Herzog TJ; Aracil M; Nieto A; Badri N; Parekh TV; Tanović A; Galmarini CM
    Gynecol Oncol; 2014 Jan; 132(1):176-80. PubMed ID: 24211400
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A phase 3 randomized, open-label, multicenter trial for safety and efficacy of combined trabectedin and pegylated liposomal doxorubicin therapy for recurrent ovarian cancer.
    Monk BJ; Herzog TJ; Wang G; Triantos S; Maul S; Knoblauch R; McGowan T; Shalaby WSW; Coleman RL
    Gynecol Oncol; 2020 Mar; 156(3):535-544. PubMed ID: 31924332
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A Phase II clinical trial of pegylated liposomal doxorubicin and carboplatin in Japanese patients with platinum-sensitive recurrent ovarian, fallopian tube or primary peritoneal cancer.
    Nakanishi T; Aoki D; Watanabe Y; Ando Y; Tomotsugu N; Sato Y; Saito T
    Jpn J Clin Oncol; 2015 May; 45(5):422-6. PubMed ID: 25670764
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Factors to consider and questions to ask in the management of recurrent ovarian cancer: a focus on the role of trabectedin + pegylated liposomal doxorubicin.
    González-Martín A; du Bois A
    Expert Rev Anticancer Ther; 2016 Nov; 16(sup1):3-10. PubMed ID: 27797624
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Xenopatients show the need for precision medicine approach to chemotherapy in ovarian cancer.
    Erriquez J; Olivero M; Mittica G; Scalzo MS; Vaira M; De Simone M; Ponzone R; Katsaros D; Aglietta M; Calogero R; Di Renzo MF; Valabrega G
    Oncotarget; 2016 May; 7(18):26181-91. PubMed ID: 27027433
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Recurrent ovarian cancer 8 months after induction and bevacizumab consolidation: rationale for using trabectedin + pegylated liposomal doxorubicin in second line.
    Colombo N
    Expert Rev Anticancer Ther; 2018 Oct; 18(sup1):13-17. PubMed ID: 30223694
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Managing recurrent ovarian cancer in daily clinical practice: case studies and evidence review with a focus on the use of trabectedin.
    Lorusso D; González-Martín A; Ray-Coquard I
    Future Oncol; 2021 Jan; 17(3s):9-19. PubMed ID: 33353406
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Real-world experience with trabectedin for the treatment of recurrent ovarian cancer.
    Romero I; López-Guerrero JA; Pignata S
    Expert Rev Anticancer Ther; 2021 Oct; 21(10):1089-1095. PubMed ID: 34128757
    [No Abstract]   [Full Text] [Related]  

  • 57. Trabectedin + pegylated liposomal doxorubicin in third-line treatment of platinum-sensitive relapsed ovarian cancer: a case study.
    Marth C
    Expert Rev Anticancer Ther; 2018 Oct; 18(sup1):19-22. PubMed ID: 30223697
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Increasing the chances for platinum-sensitive ovarian cancer patients.
    González A
    Future Oncol; 2013 Dec; 9(12 Suppl):29-35. PubMed ID: 24195528
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Phase II randomized study of trabectedin given as two different every 3 weeks dose schedules (1.5 mg/m2 24 h or 1.3 mg/m2 3 h) to patients with relapsed, platinum-sensitive, advanced ovarian cancer.
    Del Campo JM; Roszak A; Bidzinski M; Ciuleanu TE; Hogberg T; Wojtukiewicz MZ; Poveda A; Boman K; Westermann AM; Lebedinsky C;
    Ann Oncol; 2009 Nov; 20(11):1794-802. PubMed ID: 19556318
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Trabectedin plus pegylated liposomal doxorubicin in patients with disease progression after PARP inhibitor maintenance: a real-life case-control study.
    Vertechy L; Boccia SM; Tiberi G; Avesani G; Corrado G; Fagotti A; Scambia G; Marchetti C
    Int J Gynecol Cancer; 2023 Feb; 33(2):243-249. PubMed ID: 36564097
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.